Scaling-up treatment for HIV/AIDS: lessons learned from multidrug-resistant tuberculosis
Scaling-up treatment for HIV/AIDS: lessons learned from multidrug-resistant tuberculosis
复制标题
DOI：
10.1016/s0140-6736(03)15394-9
复制
发表时间：
2004-01-24
期刊：
影响因子：
168.9
通讯作者：
Kim, JY
中科院分区：
文献类型：
--
作者：
Gupta, R;Irwin, A;Kim, JY
联合国发起了一项倡议，到2005年底使发展中国家的300万人接受抗逆转录病毒艾滋病治疗（“三五目标”）。最近在耐多药结核病方面的经验为扩大艾滋病毒/艾滋病治疗提供了经验教训。通过被称为绿灯委员会的多伙伴机制扩大对耐多药结核病的治疗，使“三五计划”相关领域取得了进展，包括政策制定、药物采购、合理使用药物和加强卫生系统。GLC的成功及其遇到的障碍为建立可持续的艾滋病毒/艾滋病治疗方案提供了见解。
The UN has launched an initiative to place 3 million people in developing countries on antiretroviral AIDS treatment by end 2005 (the 3 by 5 target). Lessons for HIV/AIDS treatment scale-up emerge from recent experience with multidrug-resistant tuberculosis. Expansion of treatment for multidrug-resistant tuberculosis through the multipartner mechanism known as the Green Light Committee (GLC) has enabled gains in areas relevant to 3 by 5, including policy development, drug procurement, rational use of drugs, and the strengthening of health systems. The successes of the GLC and the obstacles it has encountered provide insights for building sustainable HIV/AIDS treatment programmes.